Trial Profile
An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Kura Oncology
- 30 Jan 2020 Status changed from recruiting to discontinued.
- 21 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 21 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.